Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.

Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, Eber MR, Soki FN, Sadler D, Sud S, Tisdelle S, Daignault SD, Nemeth JA, Snyder LA, Wronski TJ, Pienta KJ, McCauley LK.

Cancer Res. 2012 May 15;72(10):2522-32. doi: 10.1158/0008-5472.CAN-11-2928.

2.

Antiangiogenic effects of zoledronate on cancer neovasculature.

Metcalf S, Pandha HS, Morgan R.

Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113. Review.

PMID:
22044205
3.

Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization.

Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, Kobayashi T, Miyauchi Y, Hoshi H, Iwasaki R, Miyamoto H, Hao W, Morioka H, Chiba K, Kobayashi T, Yasuda H, Penninger JM, Toyama Y, Suda T, Miyamoto T.

J Exp Med. 2011 Oct 24;208(11):2175-81. doi: 10.1084/jem.20101890. Epub 2011 Oct 17. Erratum in: J Exp Med. 2011 Dec 19;208(13):2761. Dosage error in article text.

4.

Tumour macrophages as potential targets of bisphosphonates.

Rogers TL, Holen I.

J Transl Med. 2011 Oct 17;9:177. doi: 10.1186/1479-5876-9-177. Review.

5.

Intermittent PTH(1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites.

Prisby R, Guignandon A, Vanden-Bossche A, Mac-Way F, Linossier MT, Thomas M, Laroche N, Malaval L, Langer M, Peter ZA, Peyrin F, Vico L, Lafage-Proust MH.

J Bone Miner Res. 2011 Nov;26(11):2583-96. doi: 10.1002/jbmr.459.

6.

The relationship between bone, hemopoietic stem cells, and vasculature.

Ellis SL, Grassinger J, Jones A, Borg J, Camenisch T, Haylock D, Bertoncello I, Nilsson SK.

Blood. 2011 Aug 11;118(6):1516-24. doi: 10.1182/blood-2010-08-303800. Epub 2011 Jun 14.

7.

Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.

Li X, Liao J, Park SI, Koh AJ, Sadler WD, Pienta KJ, Rosol TJ, McCauley LK.

Bone. 2011 Jun 1;48(6):1354-61. doi: 10.1016/j.bone.2011.03.687. Epub 2011 Mar 17.

8.

Bone and the hematopoietic niche: a tale of two stem cells.

Bianco P.

Blood. 2011 May 19;117(20):5281-8. doi: 10.1182/blood-2011-01-315069. Epub 2011 Mar 15. Review.

9.

Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.

Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ.

Blood. 2011 Feb 3;117(5):1540-9. doi: 10.1182/blood-2010-05-282855. Epub 2010 Dec 3.

10.

Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.

Wu X, Pang L, Lei W, Lu W, Li J, Li Z, Frassica FJ, Chen X, Wan M, Cao X.

Cell Stem Cell. 2010 Nov 5;7(5):571-80. doi: 10.1016/j.stem.2010.09.012.

12.

Phenotypically identical hemopoietic stem cells isolated from different regions of bone marrow have different biologic potential.

Grassinger J, Haylock DN, Williams B, Olsen GH, Nilsson SK.

Blood. 2010 Oct 28;116(17):3185-96. doi: 10.1182/blood-2009-12-260703. Epub 2010 Jul 14.

13.

Erythropoietin couples hematopoiesis with bone formation.

Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Wang J, Lee CH, Sud S, Pienta KJ, Krebsbach PH, Taichman RS.

PLoS One. 2010 May 27;5(5):e10853. doi: 10.1371/journal.pone.0010853.

14.

Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1.

Challen GA, Boles NC, Chambers SM, Goodell MA.

Cell Stem Cell. 2010 Mar 5;6(3):265-78. doi: 10.1016/j.stem.2010.02.002.

15.

Bisphosphonates in breast cancer: teaching an old dog new tricks.

Winter MC, Coleman RE.

Curr Opin Oncol. 2009 Nov;21(6):499-506. doi: 10.1097/CCO.0b013e328331c794. Review.

PMID:
19730102
16.

3D imaging of tissue integration with porous biomaterials.

Guldberg RE, Duvall CL, Peister A, Oest ME, Lin AS, Palmer AW, Levenston ME.

Biomaterials. 2008 Oct;29(28):3757-61. doi: 10.1016/j.biomaterials.2008.06.018. Epub 2008 Jul 16.

17.

Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche.

Jung Y, Song J, Shiozawa Y, Wang J, Wang Z, Williams B, Havens A, Schneider A, Ge C, Franceschi RT, McCauley LK, Krebsbach PH, Taichman RS.

Stem Cells. 2008 Aug;26(8):2042-51. doi: 10.1634/stemcells.2008-0149. Epub 2008 May 22.

18.

Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration.

Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, Jacobsen KA, Alaql ZS, Eberhardt AW, Gerstenfeld LC, Einhorn TA, Deng L, Clemens TL.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):686-91. doi: 10.1073/pnas.0708474105. Epub 2008 Jan 9.

19.

Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1.

Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ.

Blood. 2008 Mar 1;111(5):2621-30. Epub 2007 Dec 21.

20.

The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development.

Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, Schipani E, Clemens TL.

J Clin Invest. 2007 Jun;117(6):1616-26.

Supplemental Content

Support Center